BioMarin Pharmaceutical Inc

XMUN:BM8

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

United States of America US

Employees

3 221

IPO date

Jul 23, 1999

BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms.

The company sells mainly to hospitals, specialty pharmacies, and doctors who treat patients with these rare conditions. It earns money by selling these treatments, usually through highly specialized drug distribution channels and reimbursement from insurers and government health programs. Because its medicines target small patient groups, BioMarin depends on deep expertise in rare-disease research, regulatory approval, and patient support.

What makes BioMarin different is its focus on a narrow set of hard-to-treat diseases where few other drug makers compete directly. It is part of the orphan-drug industry, where success comes from finding patients, proving strong clinical benefit, and building trusted relationships with specialists and payers. This gives the company a business model centered on specialized science and long-term treatment demand rather than broad-volume drug sales.